COVID-19 vaccine strategies must focus on severe disease and global equity

PB McIntyre, R Aggarwal, I Jani, J Jawad, S Kochhar… - The Lancet, 2022 - thelancet.com
In September, 2020, the WHO Prioritisation Roadmap for COVID-19 vaccines gave priority to
prevention of severe disease and the highest risk groups. In July, 2021, the revised …

An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)

A Alagheband Bahrami, A Azargoonjahromi… - Cellular & molecular …, 2022 - Springer
Designing and producing an effective vaccine is the best possible way to reduce the burden
and spread of a disease. During the coronavirus disease 2019 (COVID-19) pandemic, many …

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines

J Wei, KB Pouwels, N Stoesser, PC Matthews… - Nature Medicine, 2022 - nature.com
Antibody responses are an important part of immunity after Coronavirus Disease 2019
(COVID-19) vaccination. However, antibody trajectories and the associated duration of …

Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in Tucumán, Argentina

RE Chahla, RH Tomas-Grau, SI Cazorla… - The Lancet Regional …, 2022 - thelancet.com
Summary Background Gam-COVID-Vac (SPUTNIK V) has been granted emergency use
authorization in 70 nations and has been administered to millions worldwide. However …

Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study

S Yegorov, I Kadyrova, B Negmetzhanov… - Scientific reports, 2022 - nature.com
Abstract Sputnik-V (Gam-COVID-Vac) is a heterologous, recombinant adenoviral (rAdv)
vector-based, COVID-19 vaccine now used in> 70 countries. Yet there is a shortage of data …

Immunogenicity of COVID‐19 vaccines in patients with diverse health conditions: A comprehensive systematic review

K Cho, S Park, EY Kim, A Koyanagi… - Journal of medical …, 2022 - Wiley Online Library
It remains unclear how effective COVID‐19 vaccinations will be in patients with weakened
immunity due to diseases, transplantation, and dialysis. We conducted a systematic review …

Boosting the immunogenicity of the CoronaVac SARS-CoV-2 inactivated vaccine with Huoxiang Suling Shuanghua Decoction: a randomized, double-blind, placebo …

R Tang, L Wang, J Zhang, W Fei, R Zhang… - Frontiers in …, 2024 - frontiersin.org
Introduction In light of the public health burden of the COVID-19 pandemic, boosting the
safety and immunogenicity of COVID-19 vaccines is of great concern. Numerous Traditional …

A review post-vaccination SARS-CoV-2 serological test: Method and antibody titer response

MJ Devi, S Gaffar, YW Hartati - Analytical Biochemistry, 2022 - Elsevier
The development of the Coronavirus disease 2019 (COVID-19) vaccine is one of the most
important efforts in controlling the pandemic. Serological tests are used to identify highly …

[HTML][HTML] Lasting SARS-CoV-2 specific IgG antibody response in health care workers from Venezuela, 6 months after vaccination with Sputnik V

F Claro, D Silva, JAP Bogado, HR Rangel… - International Journal of …, 2022 - Elsevier
Background Scarce information is available regarding the long-term immunogenicity of the
Sputnik V vaccine. Here Sputnik V vaccinated subjects were evaluated 6 months after …

Viral vector and nucleic acid vaccines against COVID-19: A narrative review

S Khoshnood, R Ghanavati, M Shirani… - Frontiers in …, 2022 - frontiersin.org
After about 2 years since the first detection of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infections in Wuhan, China, in December 2019 that resulted in a worldwide …